DEFA14A: Zevra Therapeutics Board Receives Unanimous Support from Proxy Advisory Firms in Director Election Contest

All three leading proxy advisory firms recommend Zevra stockholders vote for the company's director nominees and withhold on dissident nominees at the upcoming Annual Meeting.

Summary

• Zevra Therapeutics has received recommendations from ISS, Glass Lewis, and Egan-Jones, all advising stockholders to vote FOR Wendy L. Dixon, Ph.D. and Tamara A. Favorito on the WHITE proxy card and WITHHOLD on dissident nominees Travis Mickle and Arthur Regan at the May 29, 2025 Annual Meeting.
• The proxy advisors concluded that the dissident, Mangless, has not presented a compelling case for change or a clear strategy to increase stockholder value.
• The Zevra Board urges stockholders to vote using the WHITE proxy card to re-elect Wendy Dixon and Tamara Favorito as Class I directors until the 2028 Annual Meeting.
• The company highlights its significant total shareholder returns under the current management team, outperforming the broader biotech market.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the unanimous support from proxy advisory firms and the emphasis on the company's strong performance and strategic direction. The board is confident in its ability to continue delivering value to shareholders.

Positives

• Unanimous endorsement from leading proxy advisory firms validates the current Board and strategic direction.
• Proxy advisors recognize the significant value creation delivered under current leadership.
• Zevra has meaningfully outperformed the broader biotech market.
• The company has experienced exceptional returns in the past two years, outpacing the total market and the S&P Biotech ETF.

Negatives

• A dissident stockholder, Mangless, is attempting to elect nominees to the Board.
• Proxy advisors question the relevant expertise of Mangless' nominees.
• ISS expresses concerns about potential disruption from having a former CEO on the board.

Risks

• The company acknowledges that forward-looking statements are subject to uncertainties, risks, and other important factors that may cause actual results to differ materially.
• Electing the dissident nominees would be disruptive and could impede value creation.

Future Outlook

The company aims to enhance stockholder value through strategic, financial, operational, corporate governance, executive compensation, and product development objectives.

Management Comments

• We are pleased that all three leading proxy advisory firms ISS, Glass Lewis, and Egan-Jones unanimously endorsed Zevras current Board and strategic direction.
• Our Board and management team remain committed to serving our stockholders and continuing the significant value creation weve delivered under current leadership.

Industry Context

The announcement highlights the importance of proxy advisory firms' recommendations in influencing shareholder votes, particularly in contested director elections. It reflects the increasing scrutiny on corporate governance and the need for companies to demonstrate value creation to maintain shareholder support.

Comparison to Industry Standards

• The document states that Zevra has meaningfully outperformed the broader biotech market over all periods of measurement.
• The document states that Zevra has outpaced both the total market (as represented by the VTI) and the S&P Biotech ETF (XBI).

Stakeholder Impact

• Shareholders are encouraged to vote in line with the Board's recommendations to protect their investment.
• The outcome of the director election will impact the company's strategic direction and management.

Next Steps

• Stockholders are urged to vote using the WHITE proxy card before the Annual Meeting on May 29, 2025.

Key Dates

Keywords

proxy, Zevra Therapeutics, stockholders, directors, Annual Meeting, ISS, Glass Lewis, Egan-Jones, Mangless, vote